Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sexual Desire Clear all

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Placebo, 0.5 mgTestosterone + 10 mg Buspirone; Drug
Lead sponsor: Emotional Brain NY Inc.; Industry
Eligibility: 21 Years to 70 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: San Diego, California • Bradenton, Florida • Orlando, Florida + 7 more

Conditions: Relieves Vaginal Dryness / Improves Self-Lubrication, Improves Strength & Elasticity of Vagina (Aka Collagen and Elastin), Improves Vaginal Wall Thickness, Reduces Pain During Sex, Reduces Vaginal Odor, Improves Vaginal Microbiome i.e. Increases Lactobacilli, Reduces Vaginal Itching, Improves Vaginal Burning & Discharge, Lowers Vaginal pH to 3.8-4.5, Improves Libido / Sexual Desire, Improves Orgasm / Sexual Satisfaction
Interventions: Intervention; Dietary Supplement
Lead sponsor: NeuEve; Industry
Eligibility: 55 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Oral Testosterone Undecanoate; Drug
Lead sponsor: San Diego Sexual Medicine; Other
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hypoactive Sexual Desire Disorder, Female Sexual Arousal Disorder, Female Orgasmic Disorder, Major Depressive Disorder, Post-traumatic Stress Disorder
Interventions: Expressive writing; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Male Infertility, Low Sperm Quality, Low Testosterone, Low Energy, Low Libido
Interventions: WeNatal For Him Supplement; Dietary Supplement
Lead sponsor: WeNatal; Industry
Eligibility: 30 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined), Sexual Interest/Arousal Disorder (DSM-5 Defined)
Interventions: bupropion, Lorexys low-dose, Lorexys moderate-dose; Drug
Lead sponsor: S1 Biopharma, Inc.; Industry
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Beachwood, Ohio • Cincinnati, Ohio

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Bremelanotide, Placebo; Drug
Lead sponsor: Palatin Technologies, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 87
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 78 more

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Testosterone Transdermal System, Placebo; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 20 Years to 70 Years · Female only
Enrollment: 562 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Hypoactive Sexual Desire Disorder (HSDD)
Interventions: Testosterone Transdermal System, Placebo patch; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Female Sexual Dysfunction
Interventions: Transcutaneous Electrical Nerve Stimulation; Device
Lead sponsor: Timothy Bruns; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Low Libido
Interventions: Flibanserin, Placebo; Drug
Lead sponsor: Mohit Khera; Other
Eligibility: 18 Years to 69 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sexual Dysfunctions, Psychological
Interventions: flibanserin; Drug
Lead sponsor: Sprout Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 596 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 88
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 72 more

Conditions: Cancer Survivor, Sexual Dysfunction, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: therapeutic testosterone, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 16
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Urbana, Illinois + 13 more

Conditions: Sexual Dysfunctions, Psychological
Interventions: flibanserin 100 mg dose every evening; Drug
Lead sponsor: Sprout Pharmaceuticals, Inc; Industry
Eligibility: Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Orlando, Florida • Wichita, Kansas • Kalamazoo, Michigan + 1 more

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Testosterone Transdermal System, Placebo patch; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Sexual Dysfunction, Psychological
Interventions: Non-prescription Zestra(TM): patented formulation; Drug
Lead sponsor: QualiLife Pharmaceuticals; Industry
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 13
States / cities: Tarzana, California • Aurora, Colorado • Aventura, Florida + 10 more

Conditions: Hypoactive Sexual Desire Disorder
Interventions: testosterone gel, placebo gel; Drug
Lead sponsor: BioSante Pharmaceuticals; Industry
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 66
States / cities: Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 60 more

Conditions: Hypogonadism, Late Onset Hypogonadism, Low Testosterone
Interventions: Dihydrotestosterone (0.7%) in hydroalcoholic gel; Drug
Lead sponsor: ASCEND Therapeutics; Industry
Eligibility: 55 Years to 80 Years · Male only
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 16
States / cities: Phoenix, Arizona • Torrance, California • Gainesville, Florida + 13 more

Conditions: Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder
Interventions: bremelanotide; Drug
Lead sponsor: Palatin Technologies, Inc; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 65
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 60 more

Conditions: Sex Disorders
Interventions: testosterone enanthate, duastride; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 21 Years to 40 Years · Male only
Enrollment: 184 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypoactive Sexual Desire Disorder (HSDD)
Interventions: Placebo Vaginal Insert, Prasterone 6.5 mg (0.50%) Vaginal Insert; Drug
Lead sponsor: EndoCeutics Inc.; Industry
Eligibility: 40 Years to 80 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 10
States / cities: Huntsville, Alabama • San Diego, California • New London, Connecticut + 7 more

Conditions: Sexuality, Sexual Dysfunction, Sexual Desire Disorder, Hypoactive Sexual Desire Disorder, Orgasmic Disorder, Pelvic Organ Prolapse, Urinary Incontinence, Interstitial Cystitis, Pelvic Floor Disorders, Female Sexual Dysfunction
Interventions: Vibrator; Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Flibanserin, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 21 Years to 74 Years · Female only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sexual Dysfunction, Physiological
Interventions: Testosterone Cream, Estring; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder

A Clinical Trial to Evaluate the Effects of the NeuEve Dryness Treatment Kit on Vaginal Health, Comfort, and Quality of Life in Postmenopausal Women

An Open-Label Study of 50 Mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women with Low Testosterone and HSDD

Effects of Early Abuse on Adult Intimate Relationships

A Clinical Trial to Evaluate the Effects of a Supplement on Markers of Male Fertility

Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

Surface Stimulation for Female Sexual Dysfunction

Hypoactive Sexual Desire Disorder in Males

A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder

Low-Dose Testosterone in Improving Libido in Postmenopausal Female Cancer Survivors

Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

Zestra in Women With Mixed Sexual Dysfunction

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

The Effect of 5-Alpha Reductase on Testosterone in Men

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

Improving Female Sexual Wellness

Effects of Flibanserin on the Pre- and Post-menopausal Female Brain

Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients